ZIM
NTLA icon

Zacks Investment Management’s Intellia Therapeutics NTLA Stock Holding History

Zacks Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-18,002
Closed -$254K – 657
2017
Q1 		$254K Buy
+18,002
New +$242K 0.01% 525

Other funds holding NTLA

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Zacks Investment Management's NTLA Position: Q2 2017 in Review

Zacks Investment Management sold out of Intellia Therapeutics (NTLA) in Q2 2017, closing a stake of 18,002 shares — an estimated $254K sold.

Zacks Investment Management first reported a position in NTLA in Q1 2017 and held it in 1 quarter. The position peaked at $254K in Q1 2017. 85 funds tracked by Wall St. Rank hold NTLA as of Q2 2017.

  • Zacks Investment Management reported no remaining Intellia Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Zacks Investment Management sold 18,002 Intellia Therapeutics shares in Q2 2017, an estimated $254K.
  • Zacks Investment Management first reported a position in Intellia Therapeutics in Q1 2017 and held it in 1 quarter.
  • Zacks Investment Management's Intellia Therapeutics position peaked at $254K in Q1 2017.
  • 85 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2017.

Based on Zacks Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.